Elagolix suppresses ovulation in a dose-dependent manner: Results from a 3-month, randomized study in ovulatory women.

CONCLUSION: Women being treated with elagolix may ovulate and should use effective methods of contraception. The rate of ovulation was lowest with elagolix 300 mg BID plus E2/NETA 1/0.5 mg QD. PMID: 31650182 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31650182?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - October 24, 2019 Category: Endocrinology Authors: Archer DF, Ng J, Chwalisz K, Chiu YL, Feinberg EC, Miller CE, Feldman RA, Klein CE Tags: J Clin Endocrinol Metab Source Type: research